Establishing the cause of chronic pain is crucial because treatment based on the mechanism of the pain is most likely to be successful. In part 1 of this 2-part article (CONSULTANT, April 1, 2008), we discussed the management of pain associated with knee osteoarthritis. Here we focus on the diagnosis and treatment of trigeminal neuralgia and radicular low back pain.
Trigeminal neuralgia presents with sudden, primarily unilateral, brief, stabbing, recurrent pain in the distribution of 1 or more branches of the fifth cranial nerve.1 Although trigeminal neuralgia is the most common cranial nerve neuralgia, the yearly incidence is only about 4 per 100,000, increasing to 20 per 100,000 after the age of 60 years.2 Women are more often affected than men.
Pathophysiology. Trigeminal neuralgia can be classified as primary (idiopathic) or secondary (symptomatic). Underlying processes associated with the secondary form include demyelinating disease, such as multiple sclerosis (often bilateral) or a posterior fossa tumor (eg, meningioma). Studies have suggested that about 10% of patients with trigeminal neuralgia may have a causative intracranial lesion.3
Although there are multiple theories, the exact pathophysiology of trigeminal neuralgia is unknown. One of the current theories supported by ultrastructural analysis is the ignition hypothesis. According to this theory, sensory axons of cranial nerve V become demyelinated in the primary form because of sustained or pulsatile microvascular compression of the trigeminal nerve or ganglia. In the secondary form, demyelination occurs because of compression from a tumor or multiple sclerosis lesion. Once structural damage has occurred to cranial nerve V or its ganglia, ectopic impulse discharges, spontaneous and triggered after discharges, and crossed excitation among neighboring afferent fibers can all lead to pain paroxysms. This could explain why these patients have trigger areas, since electrical activity from A-beta fibers (which respond to light touch) activates nociceptive fibers (C and A-delta fibers).4
Diagnosis. In the idiopathic and secondary forms, the attacks are periodic and of short duration, often with lucid intervals. The patient typically describes sharp, shooting, unilateral pain usually in the distribution of the maxillary branch of the fifth cranial nerve (V2) or the mandibular branch (V3). The ophthalmic branch (V1) is involved in fewer than 5% of cases. If V1 is involved, other possible diagnoses, including postherpetic neuralgia, should be excluded. The right cranial nerve V is affected more often than the left; the right to left ratio is 1.5 in the primary form and 2.4 in the secondary.5
Patients often describe activities that bring about symptoms, including chewing, toothbrushing, or hair-brushing, and they often have associated tactile trigger areas. If a patient has pain with swallowing, consider glossopharyngeal nerve neuralgia.1
The secondary form of trigeminal neuralgia typically affects younger persons. Any patient younger than 40 years who has trigeminal neuralgia should undergo a workup for an underlying disease process. In most patients who have the primary form, the results of sensory and motor neurological examinations are normal.
Other diagnoses that can be included in the differential for unilateral facial pain and that must be excluded are:
• Dental pain (eg, pulpitis, fractured tooth, temporomandibular joint disorder, phantom tooth pain).
• Temporal arteritis.
• Cluster headache.
• A cavernous sinus lesion (often a metastatic lesion from the breast, lung, or prostate).
• Postherpetic neuralgia.
A misunderstood cause of facial pain is atypical facial pain syndrome (pain of unknown origin). The diagnosis of atypical facial pain should be made only after all other causes have been ruled out. Unlike patients with trigeminal neuralgia, these patients complain of constant, poorly localized pain often without pain-free intervals or trigger areas. Use of the McGill Pain Questionnaire with close attention to descriptor choice can help distinguish atypical facial pain from trigeminal neuralgia.6 If the history and physical examination suggest either primary or secondary trigeminal neuralgia, additional studies are warranted, including an MRI scan with gadolinium and thin cuts (less than 1 mm) through the trigeminal nerve.7 Particular attention should be paid to the cavernous sinus and Meckel cavity, where the gasserian ganglion is located. The MRI scan can help identify or rule out underlying mass lesions, vascular compression of cranial nerve V, and demyelinating lesions. If multiple sclerosis is suspected, a lumbar puncture can be ordered. Neurophysiological diagnostic testing of the trigeminal reflexes can help differentiate primary (normal reflexes) and secondary trigeminal neuralgia with a sensitivity of 96% and a specificity of 93%.5,8
Medical therapy. The first line of treatment for trigeminal neuralgia is medical management. Once the diagnosis has been made and treatment options are being discussed, a resource to which patients can be referred for more information is the Trigeminal Neuralgia Association Web site (http://www.fpa-support.org). More than 50% of patients with trigeminal neuralgia have periods of remission that can last longer than 6 months.1 Thus, at the start of treatment, it is important to suggest to the patient that the drug dosage can be tapered as soon as 12 weeks after adequate pain control has been achieved.
A baseline blood and metabolic profile is needed before drug therapy is started. (Table 1 lists selected medications for trigeminal neuralgia.) Initially, monotherapy is used. If this is ineffective or if side effects occur, a second agent can be added. Carbamazepine, an anticonvulsant, is one of the most studied medications, and its efficacy has been demonstrated.9 A slow titration is started at 100 mg PO bid. The dose is increased by 50- to 100-mg increments up to a maximum dosage of 1200 mg/d based on efficacy, side-effect profile, and serum levels (4 to 12 µg/mL). Order laboratory studies at 1-month intervals during the initiation of treatment with close attention to the possible development of blood dyscrasias (aplastic anemia, agranulocytosis) and hyponatremia. Other adverse effects associated with carbamazepine include somnolence, gait disturbances, and a rash that can develop into Stevens-Johnson syndrome.
Oxcarbazepine, which is associated with fewer adverse effects, can be used instead of carbamazepine. Start with a dosage of 150 mg PO bid, and increase up to a total daily dose of 600 to 2400 mg/d. The median effective total daily dose of oxcarbazepine for newly diagnosed trigeminal neuralgia is 750 mg (1200 mg for refractory disease). In a small study, lamotrigine was effective in treating refractory trigeminal neuralgia at a maintenance dosage of 400 mg/d.10 Other medications that can be used as a sole agent or in combination with carbamazepine or oxcarbazepine are gabapentin,11 pregabalin,12 tricyclic antidepressants (amitriptyline, nortriptyline), and baclofen.7 Second-generation agents such as pregabalin (dose range, 150 to 600 mg/d) and gabapentin (up to 3600 mg/d) have fewer adverse effects than first-line agents, but they have not been as extensively studied in trigeminal neuralgia. Thus, evidence of their efficacy is based on case reports and extrapolation from other neuropathic pain models.13,14 Opioids are not first-line agents for trigeminal neuralgia, and their use should be restricted to short periods in which rescue medications are needed.
1. Hentschel K, Capobianco DJ, Dodick DW. Facial pain. Neurologist. 2005;11:244-249.
2. Manzoni GC, Torelli P. Epidemiology of typical and atypical craniofacial neuralgias. Neurol Sci. 2005;26(suppl 2):S65-S67.
3. Cheng TM, Cascino TL, Onofrio BM. Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors. Neurology. 1993;
4. Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained
during microvascular decompression surgery. J Neurosurg. 2002;96:532-543.
5. Truini A, Galeotti F, Cruccu G. New insight into trigeminal neuralgia. J Headache Pain. 2005;6:237-239.
6. Melzack R, Terrence C, Fromm G, Amsel R. Trigeminal neuralgia and atypical facial pain: use of the McGill Pain Questionnaire for discrimination and diagnosis. Pain. 1986;27:297-302.
7. Cohen J. Role of the neurologist in the evaluation and treatment of patients with trigeminal neuralgia. Neurosurg Focus. 2005;18:e2.
8. Cruccu G, Biasiotta A, Galeotti F, et al. Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia. Neurology. 2006;66:139-141.
9. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD005451.
10. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73:223-230.
11. Sist TC, Filadora VA 2nd, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg Anesth. 1997;22:473-478.
12. Gilron I, Flatters SJ. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag. 2006;11(suppl A):16A-29A.
13. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
14. Beniczky S, Tajti J, Timea Varga E, VŽcsei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm. 2005;
15. Broggi G, Ferroli P, Franzini A, Galosi L. The role of surgery in the treatment of typical and atypical facial pain. Neurol Sci. 2005;26(suppl 2):S95-S100.
16. Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334:1077-1083.
17. Taha JM, Tew JM Jr, Buncher CR. A prospective 15-year follow up of 154 consecutive patients with trigeminal neuralgia treated by percutaneous stereotactic radiofrequency thermal rhizotomy. J Neurosurg. 1995;83:989-993.
18. Scrivani SJ. Trigeminal neuralgia. Pain Management Rounds. 2004;1(3) Available at: http://www.painmanagementrounds.org. Accessed March 27, 2008.
19. Awad JN, Moskovich R. Lumbar disc herniations: surgical versus nonsurgical treatment. Clin Orthop Relat Res. 2006;443:183-197.
20. Modic MT, Obuchowski NA, Ross JS, et al. Acute low back pain and radiculopathy: MR imaging findings and their prognostic role and effect on outcome. Radiology. 2005;237:597-604.
21. DeLeo JA, Winkelstein BA. Physiology of chronic spinal pain syndromes: from animal models to biomechanics. Spine. 2002;27:2526-2537.
22. Bush K, Cowan N, Katz DE, Gishen P. The natural history of sciatica associated with disc pathology. A prospective study with clinical and independent radiologic follow-up. Spine. 1992;17:1205-1212.
23. Jensen TS, Albert HB, Soerensen JS, et al. Natural course of disc morphology in patients with sciatica: an MRI study using a standardized qualitative classification system. Spine. 2006;31:1605-1613.
24. Garfin SR, Vaccaro AR, eds. Orthopedic Knowledge Update: Spine. Rosemont, Ill: American Academy of Orthopedic Surgeons; 1997.
25. Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. J Spinal Disord. 2000;13:463-469.
26. LaBuda CJ, Little PJ. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods. 2005;144: 175-181.
27. Benzon H, Raja SN, Molloy RE, et al, eds. Essentials of Pain Medicine and Regional Anesthesia. 2nd ed. Philadelphia: Elsevier; 2005.
28. Lemberg K, Kontinen VK, Viljakka K, et al. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg. 2006;102:1768-1774.
29. Clarke J, van Tulder M, Blomberg S, et al. Traction for low back pain with or without sciatica: an updated systematic review within the framework of the Cochrane collaboration. Spine. 2006;31:1591-1599.
30. McLain RF, Kapural L, Mekhail NA. Epidural steroids for back and leg pain: mechanism of action and efficacy. Cleve Clin J Med. 2004;71:961-970.
31. DePalma MJ, Bhargava A, Slipman CW. A critical appraisal of the evidence for selective nerve root injection in the treatment of lumbosacral radiculopathy. Arch Phys Med Rehabil. 2005;86:1477-1483.
32. Weinstein SM, Herring SA; NASS (National American Spine Society). Lumbar epidural steroid injections. Spine J. 2003;3(3 suppl):37S-44S.
33. Buttermann GR. Treatment of lumbar disc herniation: epidural steroid injection compared with discectomy. A prospective, randomized study. J Bone Joint Surg Am. 2004;86:670-679.
34. Dubourg G, Rozenberg S, Fautrel B, et al. A pilot study on the recovery from paresis after lumbar disc herniation. Spine. 2002;27:1426-1431.
35. Atlas SJ, Keller RB, Wu YA, et al. Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine. 2005;30:936-943.
36. North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005;56:98-107.